1-6 of 6
Dan Zheng
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Primary Analysis of ZUMA-2 Cohort 3: Brexucabtagene Autoleucel (Brexu-Cel) in Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Who Were Naive to Bruton Tyrosine Kinase Inhibitors (BTKi)

Tom van Meerten, M.J. Kersten, Gloria Iacoboni, Georg Hess, Pim Mutsaers, Alejandro Martín García-Sancho, Andre Goy, Eva Gine, Brian T. Hill, Wen-Kai Weng, Martin Dreyling, Patrick M. Reagan, Krish Patel, Ahmed Galal, Charles Herbaux, Robin Sanderson, Dan Zheng, Justyna Kanska, Wangshu Zhang, Rita Damico Khalid, Ioana Kloos, Michael Wang
Journal: Blood
Blood (2024) 144 (Supplement 1): 748.
https://doi.org/10.1182/blood-2024-198021
Published: 2024
Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Michael Wang, Andre Goy, Javier Munoz, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Rhine Shen, Wangshu Zhang, Rita Damico Khalid, Ioana Kloos, Patrick M. Reagan
Journal: Blood
Blood (2024) 144 (Supplement 1): 4388.
https://doi.org/10.1182/blood-2024-198018
Published: 2024
Journal Articles

A Propensity Score-Matched Analysis on the Outcomes of Brexucabtagene Autoleucel from Zuma-2 Study and Allogeneic Stem Cell Transplantation from the EBMT Database in Relapsed and Refractory Post-Btki Mantle Cell Lymphoma

Nora Liebers, Hervé Finel, Dominic Edelmann, Guido Kobbe, Ben-Niklas Bärmann, Yasmina Serroukh, Didier Blaise, Dietrich W. Beelen, Carlos Solano, Maija Itäla-remes, Annoek E.C. Broers, Goda Choi, Nicolaus Kroeger, Jenny Louise Byrne, Jean-Jacques Tudesq, Ana Nunes, Rubina Siddiqi, Elande Baro, Dan Zheng, Ioana Kloos, Peter Dreger, Anna Maria Sureda Balari, Bertram Glass, Sascha Dietrich
Journal: Blood
Blood (2023) 142 (Supplement 1): 3494.
https://doi.org/10.1182/blood-2023-174368
Published: 2023
Journal Articles

Outcomes of Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 and ZUMA-18, an Expanded Access Study

Andre Goy, Caron A. Jacobson, Ian W. Flinn, Brian T. Hill, Wen-Kai Weng, Luke Mountjoy, Oluwole Olalekan, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 106.
https://doi.org/10.1182/blood-2023-174273
Published: 2023
Journal Articles

Assessment of Early Intervention Strategies for Management of Cytokine Release Syndrome and Neurologic Events after Brexucabtagene Autoleucel (Brexu-Cel) Treatment in Patients with Relapsed or Refractory Mantle Cell Lymphoma (R/R MCL) in ZUMA-2

Olalekan O. Oluwole, Patrick M. Reagan, David B. Miklos, Frederick L. Locke, Andre Goy, Caron A. Jacobson, Javier L. Munoz, Edouard Forcade, Max S. Topp, Dan Zheng, Ana Nunes, Wangshu Zhang, Rhine R. Shen, Ioana Kloos, Marie José Kersten, Michael L. Wang
Journal: Blood
Blood (2023) 142 (Supplement 1): 2120.
https://doi.org/10.1182/blood-2023-174681
Published: 2023
Journal Articles

Assessment of Durable Responses after Brexucabtagene Autoleucel (KTE-X19) in the ZUMA-2 Study in Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL)

Javier Munoz, Patrick M. Reagan, Andre H. Goy, David B. Miklos, Dan Zheng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Marie José Kersten, Michael Wang
Journal: Blood
Blood (2022) 140 (Supplement 1): 9320–9322.
https://doi.org/10.1182/blood-2022-158097
Published: 2022